NEW YORK, Jan. 29, 2026 /PRNewswire/ — LYMA, the luxury regenerative MedTech company, today revealed its financial results for the year ending 31 December 2025, reporting revenues of $48 million and EBITDA of $7 million, marking a year of significant growth driven by successful expansion in the United States market.
The strong performance reflects LYMA’s strategic focus on the US market, where the brand achieved notable momentum following the April 2025 launch of its LYMA PRO. The US market has emerged as a key growth driver for the brand, with increasing consumer demand for science-backed regenerative skincare technology and now represents over 70 per cent of its global sales.
Following more than 18 months investment and focus on gaining FDA Clearance the Laser PRO launched in the US in April 2025 and since then has been making its American Dream a reality with key milestones including:
- Record-breaking waitlist: Thousands of Americans joined LYMA’s waitlist ahead of the 15 April launch—over 16,000 people, representing more than $100 million in demand for a device priced at nearly $6,000.
- Exceeding sales expectations: Initial sales exceeded expectations in its …